+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension

Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension

Free Radical Biology and Medicine 56: 28-43

Pulmonary arterial hypertension (PH) is a fatal disease marked by excessive pulmonary vascular cell proliferation. Patients with idiopathic PH express endothelin-1 (ET-1) at high levels in their lungs. As the activation of both types of ET-1 receptor (ETA and ETB) leads to increased generation of superoxide and hydrogen peroxide, this may contribute to the severe oxidative stress found in PH patients. As a number of pathways may induce oxidative stress, the particular role of ET-1 remains unclear. The aim of this study was to determine whether inhibition of ET-1 signaling could reduce pulmonary oxidative stress and attenuate the progression of disease in rats with occlusive-angioproliferative PH induced by a single dose of SU5416 (200 mg/kg) and subsequent exposure to hypoxia for 21 days. Using this regimen, animals developed severe PH as evidenced by a progressive increase in right-ventricle (RV) peak systolic pressure (RVPSP), severe RV hypertrophy, and pulmonary endothelial and smooth muscle cell proliferation, resulting in plexiform vasculopathy. PH rats also had increased oxidative stress, correlating with endothelial nitric oxide synthase uncoupling and NADPH oxidase activation, leading to enhanced protein nitration and increases in markers of vascular remodeling. Treatment with the combined ET receptor antagonist bosentan (250 mg/kg/day; day 10 to 21) prevented further increase in RVPSP and RV hypertrophy, decreased ETA/ETB protein levels, reduced oxidative stress and protein nitration, and resulted in marked attenuation of pulmonary vascular cell proliferation. We conclude that inhibition of ET-1 signaling significantly attenuates the oxidative and nitrosative stress associated with PH and prevents its progression.

(PDF emailed within 0-6 h: $19.90)

Accession: 051850016

Download citation: RISBibTeXText

PMID: 23200808

DOI: 10.1016/j.freeradbiomed.2012.09.013

Related references

Oxidative and nitrosative stress in pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide. Vascular Pharmacology 45(5): 308-316, 2006

Cytochemical and Immunocytochemical Localization of Oxidative and Nitrosative Stress in Pulmonary Hypertension in Lungs of Broiler Chickens, Gallus domesticus. Microscopy and Microanalysis 16(S2): 964-965, 2010

Oxidative-Nitrosative Stress In Hypertension. Current Vascular Pharmacology 3(3): 231-246, 2005

Oxidative-nitrosative stress in hypertension. Current Vascular Pharmacology 3(3): 231-246, 2005

Oxidative stress and nitrosative stress are involved in different stages of proteolytic pulmonary emphysema. Free Radical Biology and Medicine 53(11): 1993-2001, 2013

Can Diabetes I and Early Blindness Be Prevented Using a Tylenol Combination Which Inhibits Oxidative and Nitrosative Stress?. 2012

Can diabetes I and early blindness be prevented using a tylenol combination which inhibits oxidative and nitrosative stress?. Isrn Toxicology 2011: 461928, 2011

Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies. Pharmacology and Therapeutics 165: 50-62, 2017

Oxidative and nitrosative stress during pulmonary ischemia-reperfusion injury: from the lab to the OR. Annals of Translational Medicine 5(6): 131, 2017

Oxidative/Nitrosative stress and the pathobiology of chronic obstructive pulmonary disease. Journal of Clinical and Diagnostic Research 7(3): 580-588, 2013

Oxidative and nitrosative stress are involved in different stages of proteolytic pulmonary emphysema. 2012

Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Medical Weekly 137(41-42): 573-580, 2007

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Journal of the American College of Cardiology 52(25): 2127-2134, 2009

Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. Faseb Journal 24(4): 1192-1204, 2010

Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Targets 22(12): 1049-1061, 2018